05.02.2019 Merck KGaA  DE0006599905

DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology


 

DGAP-Ad-hoc: Merck KGaA / Key word(s): Alliance
Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology

05-Feb-2019 / 12:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Merck KGaA and GlaxoSmithKline plc (GSK) will collaborate closely in the field of immuno-oncology. The cooperation relates to M7824, a bifunctional fusion protein developed by Merck. This is currently in clinical development and targets various forms of cancer that are difficult to treat.
 
Merck will receive an upfront payment of EUR300 million and is eligible for potential development milestone payments of up to EUR500 million. Merck will also be eligible for further payments upon successfully achieving future approval and commercial milestones of up to EUR2.9 billion. The total potential deal value is up to EUR3.7 billion.
 
The two companies will jointly develop and commercialize M7824. All profits and costs from the collaboration will be shared equally on a global basis.
 
In total, eight high priority clinical development studies for M7824 are ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.
 


Contact:
Friederike Segeberg, Head of Media Relations

05-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 6328
Fax: +49 (0)6151 72 - 3183
E-mail: [email protected]
Internet: www.merck.de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX

 
End of Announcement DGAP News Service

772413  05-Feb-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=772413&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 15.327,00 14.836,00 16.152,00 17.534,00 19.687,00 22.232,00 20.993,00
EBITDA1,2 4.282,00 3.528,00 4.066,00 4.923,00 5.946,00 6.504,00 5.489,00
EBITDA-Marge3 27,94 23,78 25,17 28,08 30,20 29,26
EBIT1,4 2.525,00 1.727,00 2.120,00 2.985,00 4.179,00 4.474,00 3.609,00
EBIT-Marge5 16,47 11,64 13,13 17,02 21,23 20,12 17,19
Jahresüberschuss1 2.610,00 3.396,00 1.324,00 1.994,00 3.065,00 3.339,00 2.834,00
Netto-Marge6 17,03 22,89 8,20 11,37 15,57 15,02 13,50
Cashflow1,7 2.696,00 2.219,00 2.856,00 3.477,00 4.616,00 4.259,00 3.784,00
Ergebnis je Aktie8 5,99 7,76 3,04 4,57 7,03 7,65 6,49
Dividende8 1,25 1,25 1,30 1,40 1,85 2,20 1,20
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Merck
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659990 163,800 Halten 71.216,62
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,27 25,30 0,87 29,39
KBV KCV KUV EV/EBITDA
2,70 18,82 3,39 14,84
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
2,20 2,20 1,34 26.04.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
15.05.2024 01.08.2024 14.11.2024 07.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,37% 5,99% 13,67% 5,51%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Merck KGaA  ISIN: DE0006599905 können Sie bei EQS abrufen


Gesundheit , 659990 , MRK , XETR:MRK